Complexes of protein crystals and ionic polymers
The present invention relates to complexes of protein crystals and ionic polymers and compositions comprising such complexes. The invention further provides methods for producing these complexes and compositions. The invention further provides methods for treatment of an individual having a disease requiring or ameliorated by sustained release of protein-based therapies.
1 . A complex comprising a protein crystal and an ionic compound.
2 . The complex according to claim 1 , wherein said protein is selected from the group consisting of: therapeutic proteins, fusion proteins, glycoproteins, receptors, synthetic antigens, recombinant antigens, viral surface proteins, hormones, antibodies, enzymes, Fab fragments, cyclic peptides, linear peptides.
3 . The complex according to claim 2 , wherein said therapeutic protein is selected from the group consisting of: glucagon-like peptide 1, antibodies, histocompatibility antigens, integrins, selecting, inhibitors, growth factors, postridical hormones, nerve growth hormones, blood clotting factors, adhesion molecules, bone morphogenic proteins, lectins, trophic factors, cytokines such as TGF-β, IL-2, IL-4, α-IFN, β-IFN, γ-IFN, TNF, IL-6, IL-8, lymphotoxin, IL-5, Migration inhibition factor, GMCSF, IL-7, IL-3, monocyte-macrophage colony stimulating factors, granulocyte colony stimulating factors, multidrug resistance proteins, other lymphokines, toxoids, erythropoietin, Factor VIII, amylin, TPA, dornase-α, α-1-antitrypsin, human growth hormones, nerve growth hormones, bone morphogenic proteins, growth differentiation factors, neuregulin, urease and toxoids.
4 . The complex according to claim 2 , wherein said hormone is selected from the group consisting of: human growth hormone, glucagons, parathyroid hormone, fertility hormones, lutenizing hormone and follicle stimulating hormone.
5 . The complex according to claim 2 , wherein said antibody is selected from the group consisting of: Infliximab, Etanercept, Rituximab, trastuzumab, Abciximab, Palivizumab, Murumonab-CD3, Gemtuzumab, Basiliximab, Daclizumab, Zevalin and Mylotarg.
6 . The complex according to claim 2 , wherein said enzyme is selected from the group consisting of: rasburicase, lipase, amylase, hydrolases, oxidases, isomerases, lyases, ligases, adenylate cyclases, transferases, oxidoreductases, nitrilases, laccase, dehydrogenase, peroxidases and hydantoinase.
7 . The complex according to claim 1 , wherein said ionic compound is selected from the group consisting of: polymers, polypeptides, oligopeptides, proteins and dendrimers.
8 . The complex according to claim 7 , wherein said polypeptide or protein component of said ionic compound has a molecular weight of greater than about 2 kD.
9 . The complex according to claim 7 , wherein said polypeptide or said protein component of said ionic compound is selected from the group consisting of: polycations and polyanions.
10 . The complex according to claim 9 , wherein said polycation is selected from the group consisting of: Protamine, polyarginine, polylysine, polyhistidine, histones, myelinbasic protein, polymyxin B sulfate, dodecyltrimethylammonium bromide, bradykinin, spermine, putrescine, octylarginine and synthetic peptides and dendrimers.
11 . The complex according to claim 9 , wherein said polyanion is selected from the group consisting of: polyglutamate, polyaspartate, polyacrylate, polycyanoacrylates, polylactate, poly-B-hydroxybutyrate, polyvinylpyrollidone, hyaluronic acid, heparin, sulfated polysaccharides, dextran sulfates, heparin sulfates and dendrimers.
12 . A composition comprising an insoluble phase suspended in a solution phase, wherein said insoluble phase is a complex comprising a protein crystal, an ionic compound and an excipient and wherein said solution phase is selected from the group consisting of: water, buffer, preservative, isotonicity agents, stabilizers and combinations thereof.
13 . The composition according to claim 12 , wherein said protein is selected from the group consisting of: therapeutic proteins, fusion proteins, glycoproteins, receptors, synthetic antigens, recombinant antigens, viral surface proteins, hormones, antibodies, enzymes, Fab fragments, cyclic peptides, linear peptides.
14 . The composition according to claim 13 , wherein said therapeutic protein is selected from the group consisting of: glucagon-like peptide 1, antibodies, histcompatibility antigens, integrins, selectins, inhibitors, growth factors, postridical hormones, nerve growth hormones, blood clotting factors, adhesion molecules, bone morphogenic proteins and lectins, trophic factors, cytokines such as TGF-β, IL-2, IL-4, α-IFN, β-IFN, γ-IFN, TNF, IL-6, IL-8, lymphotoxin, IL-5, Migration inhibition factor, GMCSF, IL-7, IL-3, monocyte-macrophage colony stimulating factors, granulocyte colony stimulating factors, multidrug resistance proteins, other lymphokines, toxoids, erythropoietin, Factor VIII, amylin, TPA, dornase-α, α-1-antitrypsin, human growth hormones, nerve growth hormones, bone morphogenic proteins, urease and toxoids.
15 . The composition according to claim 13 , wherein said hormone is selected from the group consisting of: human growth hormone, human growth hormone, glucagons, parathyroid hormone, fertility hormones, lutenizing hormone and follicle stimulating hormone.
16 . The composition according to claim 13 , wherein said antibody is selected from the group consisting of: Infliximab, Etanercept, Rituximab, trastuzumab, Abciximab, Palivizumab, Murumonab-CD3, Gemtuzumab, Basiliximab, Daclizumab, Zevalin and Mylotarg.
17 . The composition according to claim 13 , wherein said enzyme is selected from the group consisting of: rasburicase, lipase, amylase, hydrolases, oxidases, isomerases, lyases, ligases, adenylate cyclases, transferases, oxidoreductases, nitrilases, laccase, dehydrogenase, peroxidases and hydantoinase.
18 . The composition according to claim 12 , wherein said ionic compound is selected from the group consisting of: polymers, polypeptides, oligopeptides, proteins and dendrimers.
19 . The composition according to claim 18 , wherein said oligopeptide component of said ionic compound has a molecular weight of less than about 2 kD.
20 . The composition according to claim 18 , wherein said polypeptide or protein component of said ionic compound has a molecular weight of greater than about 2 kD.
21 . The composition according to claim 18 , wherein said polypeptide or said protein component of said ionic compound is selected from the group consisting of polycations and polyanions.
22 . The composition according to claim 21 , wherein said polycation is selected from the group consisting of: Protamine, polyarginine, polylysine, polyhistidine, histones, myelinbasic protein, polymyxin B sulfate, dodecyltrimethylammonium bromide, bradykinin, spermine, putrescine, octylarginine and synthetic peptides and dendrimers.
23 . The composition according to claim 21 , wherein said polyanion is selected from the group consisting of: polyglutamate, polyaspartate, polyacrylate, polycyanoacrylates, polylactate, poly-B-hydroxybutyrate, polyvinylpyrollidone, hyaluronic acid, heparin, sulfated polysaccharides, dextran sulfates, heparin sulfates and dendrimers.
24 . The composition according to claim 12 , wherein said excipient is selected from the group consisting of: detergents, pluronic polyols, polyols, glycoaminoglycans, amino acids, starch, glycerol, sugars, cellulose, povidone dextrin, polysorbates, hydroxypropyl cellulose and ascorbic acid.
25 . The composition according to claim 12 , wherein said stabilizer is selected from the group consisting of: sugars, polyols, amino acids, soluble proteins and detergents.
26 . A method for treating a disease state in a mammal, comprising the step of administering to said mammal a therapeutically effective amount of a complex according to any one of claims 1 - 11 .
27 . A method for treating a disease state in a mammal, comprising the step of administering to said mammal a therapeutically effective amount of a composition according to any one of claims 12 - 25 .
28 . The method according to claim 26 or 27 , wherein said complex or composition is administered to said mammal by oral route or parenteral route.
29 . The method according to claim 28 , wherein said complex or composition is administered to said mammal by subcutaneous or intramuscular route.
30 . The method according to claim 29 , wherein said complex or composition is administered to said mammal by subcutaneous route using a needle having a gauge greater than 27.
31 . The method according to claim 26 or 27 , wherein said complex or composition is administered to said mammal by needle-free injection or by transdermal means.
32 . The method according to claim 26 or 27 , wherein said complex or composition is administered to said mammal once a week.
33 . The method according to claim 26 or 27 , wherein said complex or composition is administered to said mammal once every two weeks.
34 . The method according to claim 26 or 27 , wherein said complex or composition is administered to said mammal once a month.
35 . The method according to claim 26 or 27 , wherein said mammal is a human.
36 . A method for producing a protein complex, comprising the steps of:
(a) mixing a solution of a protein with a crystallization reagent mix to produce a solution;
(b) adding deionized water to said solution;
(c) incubating said solution for between about 2 and about 48 hours at a temperature between about 4° C. and about 40° C., until protein crystals are formed; and
(d) adding an ionic compound to said solution.
37 . A method for producing a protein complex, comprising the steps of:
(a) mixing a solution of a protein with a crystallization buffer to produce a solution;
(b) adding deionized water to said solution;
(c) adding an ionic compound to said solution; and
(d) incubating said solution for between about 2 and about 48 hours at a temperature between about 4° C. and about 40° C., until protein crystals are formed.
38 . The method according to claim 35 or 36 , which further comprises the step of adding an excipient to said solution between steps (b) and (c).
39 . A method for producing a composition comprising a protein complex suspended in a solution phase, comprising the step of mixing said complex prepared according to claim 35 or 36 in a solution phase selected from the group consisting of: water, buffer, preservative, isotonicity agents, stabilizers and combinations thereof.
40 . The method according to claim 35 or 36 , wherein, in step (a), said protein is present in said solution at a concentration between about 0.5 mg/ml and about 200 mg/ml.
41 . The method according to claim 35 or 36 , wherein, in step (a), said crystallization reagent mix is selected from the group consisting of: Tris-HCl, HEPES, acetate, phosphate, citrate borate, imidazole, Bis-tris, bicarbonate, carbonate, N-(2-acetamido)-iminodiacetic acid and MES.
42 . The method according to claim 35 or 36 , wherein said crystallization reagent mix is present in said solution at a concentration between about 0.5 mM and about 500 mM.
43 . The method according to claim 35 or 36 , wherein said crystallization reagent mix has a pH between about 2 and about 10.
44 . The method according to claim 35 or 36 , wherein in step (d), the pH of said solution is the same as the pH of said crystallization reagent mix.
45 . The method according to claim 35 or 36 , wherein, in step (c) of claim 35 and in step (d) of claim 36 , said solution is incubated for between about one and about two days at a temperature between about 4° C. and about 37° C.
46 . The method according to claim 35 or 36 , wherein said ionic compound is selected from the group consisting of: polymers, polypeptides, oligopeptides, proteins and dendrimers.
47 . The method according to claim 45 , wherein said oligopeptide component of said ionic compound has a molecular weight of less than about 2 kD.
48 . The method according to claim 45 , wherein said polypeptide or protein component of said ionic compound has a molecular weight of greater than about 2 kD.
49 . The method according to claim 45 , wherein said polypeptide or said protein component of said ionic compound is selected from the group consisting of polycations and polyanions.
50 . The method according to claim 48 , wherein said polycation is selected from the group consisting of: Protamine, polyarginine, polylysine, polyhistidine, histones, myelinbasic protein, polymyxin B sulfate, dodecyltrimethylammonium bromide, bradykinin, spermine, putrescine, octylarginine and synthetic peptides and dendrimers.
51 . The method according to claim 48 , wherein said polyanion is selected from polyglutamate, polyaspartate, polyacrylate, polycyanoacrylates, polylactate, poly-B-hydroxybutyrate, polyvinylpyrollidone, hyaluronic acid, heparin, sulfated polysaccharides, dextran sulfates, heparin sulfates and dendrimerspolyglutamate and polyaspartate.
52 . The method according to claim 37 , wherein said excipient is selected from the group consisting of: detergents, pluronic polyols, polyols, glycoaminoglycans, amino acids, starch, glycerol, sugars, cellulose, povidone dextrin, polysotbates, hydroxypropyl cellulose and ascorbic acid.
53 . The method according to claim 38 , wherein said stabilizer is selected from the group consisting of: sugars, polyols, amino acids, soluble proteins, detergents and combinations thereof.
54 . The method according to claim 35 or 36 , wherein said protein is selected from the group consisting of: therapeutic proteins, fusion proteins, glycoproteins, receptors, synthetic antigens, recombinant antigens, viral surface proteins, hormones, antibodies, enzymes, Fab fragments, cyclic peptides, linear peptides.
55 . The method according to claim 35 or 36 , wherein said therapeutic protein is selected from the group consisting of: glucagon-like peptide 1, antibodies, histocompatibility antigens, integrins, selectins, inhibitors, growth factors, postridical hormones, nerve growth hormones, blood clotting factors, adhesion molecules, bone morphogenic proteins, lectins, trophic factors, cytokines such as TGF-β, IL-2, IL-4, α-IFN, β-IFN, γ-IFN, TNF, IL-6, IL-8, lymphotoxin, IL-5, Migration inhibition factor, GMCSF, IL-7, IL-3, monocyte-macrophage colony stimulating factors, granulocyte colony stimulating factors, multidrug resistance proteins, other lymphokines, toxoids, erythropoietin, Factor VIII, amylin, TPA, dornase-α, α-1-antitrypsin, human growth hormones, nerve growth hormones, bone morphogenic proteins, growth differentiation factors, reuregulins, urease and toxoids.
56 . The method according to claim 35 or 36 , wherein said hormone is selected from the group consisting of: human growth hormone, glucagons, parathyroid hormone, fertility hormones, lutenizing hormone and follicle stimulating hormone.
57 . The method according to claim 35 or 36 , wherein said antibody is selected from the group consisting of: Infliximab, Etanercept, Rituximab, trastuzumab, Abciximab, Palivizumab, Murumonab-CD3, Gemtuzumab, Basiliximab, Daclizumab, Zevalin and Mylotarg.
58 . The method according to claim 35 or 36 , wherein said enzyme is selected from the group consisting of: rasburicase, lipase, amylase, hydrolases, oxidases, isomerases, lyases, ligases, adenylate cyclases, transferases, oxidoreductases, nitrilases, laccase, dehydrogenase, peroxidases and hydantoinase.
59 . The method according to claim 35 or 36 , wherein said enzyme is selected from the group consisting of: Aspergillus oryzae amylase, Burkholderia cepacia lipase, oxalate oxidase and urate oxidase.
60 . The complex according to claim 1 or 2 , wherein said protein crystal is not an insulin protein crystal.